Optimal low-density lipoprotein is 50 to 70 mg/dl: Lower is better and physiologically normal

Journal of the American College of Cardiology

Volumn 43, Issue 11, 2004, Pages 2142-2146

  O'Keefe Jr , James H ^a   Cordain, Loren ^b   Harris, William H ^a   Moe, Richard M ^a   Vogel, Robert ^c  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

CHD; coronary heart disease; LDL; low density lipoprotein; Natural Cholesterol Education Program Adult Treatment Panel III; NCEP ATP III

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ATHEROSCLEROSIS; CLINICAL CHEMISTRY; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FAMILIAL HYPERCHOLESTEROLEMIA; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MUSCLE DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; HUMANS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS;

EID: 2542461241     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.03.046     Document Type: Review

References (38)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497
2. Mayor S. European society issues guidelines on cardiovascular disease. BMJ. 327:2003;518
3. Law M.R., Wald N.J. Risk factor thresholds their existence under scrutiny. BMJ. 324:2002;1570-1576
4. Akosah K.O., Schaper A., Cogbill C., et al. Preventing myocardial infarction in the young adult in the first place how do the National Cholesterol Education Panel III guidelines perform? J Am Coll Cardiol. 41:2003;1475-1479
5. Shepherd J., Cobbe S.M., Ford I., et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307
6. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of AFCAPS/TexCaPS. JAMA. 279:1998;1615-1622
7. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) a multicentre randomised controlled trial. Lancet. 361:2003;1149-1158
8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals a randomised placebo-controlled trial. Lancet. 360:2002;7-22
9. Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357
10. Sacks F.M., Pfeffer M.A., Moye L.A., et al. Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009
11. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4, 444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389
12. Cannon C.P., Braunwald E., McCabe C.H., et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 350:2004;1495-1502
13. Greenlund K.J., Zheng Z.J., Keenan N.L., et al. Trends in self-reported multiple cardiovascular disease risk factors among adults in the United States, 1991-1999. Arch Intern Med. 164:2004;181-188
14. Jaffer F.A., O'Donnell C.J., Larson M.G., et al. Age and sex distribution of subclinical aortic atherosclerosis a magnetic resonance imaging examination of the Framingham Heart Study. Arterioscler Thromb Biol. 22:2002;849-854
15. Cordain L., Eaton S.B., Brand Miller J., Mann N., Hill K. The paradoxical nature of hunter-gatherer diets meat based, yet non-atherogenic. Eur J Clin Nutr. 56:(Suppl 1):2002;S42-52
16. O'Keefe J.H., Cordain L. Cardiovascular disease resulting from a diet and lifestyle at odds with our Paleolithic genome how to become a 21st century hunter-gatherer. Mayo Clin Proc. 79:2004;101-108
17. Kemnitz J.W., Sapolsky R.M., Altmann J., et al. Effects of food availability on serum insulin and lipid concentrations in free-ranging baboons. Am J Primatol. 57:2002;13-19
18. Jukema J.W., Bruschke A.V., van Boven A.J., et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 91:1995;2528-2540
19. Blankenhorn D.H., Azen S.P., Kramsch D.M., et al. Coronary angiographic changes with lovastatin therapy the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 119:1993;969-976
20. MAAS Investigators. Effect of simvastatin on coronary atheroma the Multicentre Anti-Atheroma Study (MAAS). Lancet. 344:1994;633-638
21. Waters D., Higgenson L., Gladstone P., et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography the Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 89:1994;959-968
22. Pitt B., Mancini G.B.J., Ellis S.G., et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I). J Am Coll Cardiol. 26:1995;1133-1139
23. Herd J.A., Ballantyne C.M., Farmer J.A., et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study. [LCAS]) Am J Cardiol. 80:1997;278-286
24. Nissen S., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis a randomized controlled trial. JAMA. 291:2004;1071-1080
25. Smilde T.J., van Wissen S., Wollersheim H., Trip M.D., Kastelein J.J.P., Stalenhoef A.F.H. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP) a prospective, randomized, double-blind trial. Lancet. 357:2001;577-581
26. Taylor A.J., Kent S.M., Flaherty P.J., Coyle L.C., Markwood T.T., Vernalis M.N. ARBITER Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 106:2002;2055-2060
27. Stamler J., Daviglus M.L., Garside D.B., et al. Relationship of baseline serum cholesterol levels in three large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA. 284:2000;311-318
28. Jones P.H., Davidson M.H., Stein E.A., Bays H.E., et al. Comparison of the efficacy and safety of rosuvastatin vs atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol. 92:2003;152-160
29. Devroey D., De Swaef N., Coigniez P., Vandevoorde J., Kartounian J., Betz W. Results from a cardiovascular prevention campaign in persons aged 45 to 64 years. Int J Clin Pract. 57:2003;430-434
30. Malloy M.J., Kane J.P. Disorders involving deficiencies of lipoproteins that contain B apolipoproteins. Betteridge D.J., Illingworth D.R., Shepherd J. Lipoproteins in Health and Disease. 1999;863-877 Oxford University Press, New York, NY
31. Glueck C.J., Kelley W., Gupta A., Fontaine R.N., Wang P., Gartside P.S. Prospective 10-year evaluation of hypobetalipoproteinemia in a cohort of 772 firefighters and cross-sectional evaluation of hypocholesterolemia in 1, 479 men in the National Health and Nutrition Examination Survey I. Metabolism. 46:1997;625-633
32. Mohler E.R. III, Hiatt W.R., Creager M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 108:2003;1481-1486
33. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20, 536 people with cerebrovascular disease or other high-risk conditions. Lancet. 363:2004;757-767
34. Etminan M., Gill S., Samii A. The role of lipid-lowering drugs in cognitive function a meta-analysis of observational studies. Pharmacotherapy. 23:2003;726-730
35. McGwin G., Owsley C., Curcio C.A., Crain R.J. The association between statin use and age related maculopathy. Br J Ophthalmol. 87:2003;1121-1125
36. Bellamy M.F., Pellikka P.A., Klarich K.W., et al. Association of cholesterol levels, hydroxymethyglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol. 40:2002;1723-1730
37. Bauer B.C., Mundy G.R., Jamal S.A., et al. Use of statins and fracture results of four prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med. 164:2004;146-152
38. Wald N.J., Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 326:2003;1419